VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, is advancing a strategy to implement U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company announced that this approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
According to the company, it has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. As part of this effort, VERAXA evaluated its lead BiTAC-TCE and bsADC candidates using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies.
Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance. This news matters because it signals a potential shift in how cancer therapies are developed, addressing ethical concerns about animal testing while potentially bringing new treatments to patients faster and at lower cost. For an industry facing increasing pressure to improve efficiency and reduce reliance on animal models, VERAXA’s progress could serve as a model for others.
VERAXA Biotech AG describes itself as building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company states it is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
For more details, the full press release is available at https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Investors and readers should also review the full terms of use and disclaimers on the InvestorBrandNetwork website at https://IBN.ai/Disclaimer.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied. Undue reliance should not be placed on forward-looking statements in making an investment decision. All parties undertake no duty to update this information unless required by law.
